Antibody-mediated capture of amyloid-beta (Aβ) in peripheral blood was identified as an
attractive strategy to eliminate cerebral toxic amyloid in Alzheimer's disease (AD) patients
and murine models. Alternatively, defective capacity of peripheral monocytes to engulf Aβ
was reported in individuals with AD. In this report, we developed different approaches to
investigate cellular uptake and phagocytosis of Aβ, and to examine how two immunological
devices–an immunostimulatory Adjuvant System and different amyloid specific antibodies …